Skip to content

Clinical study on the safety and efficacy of estradiol silicone rubber uterine drug delivery system in promoting endometrial repair after artificial abortion

Clinical study on the safety and efficacy of estradiol silicone rubber uterine drug delivery system in promoting endometrial repair after artificial abortion

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500111804
Enrollment
Unknown
Registered
2025-11-06
Start date
2025-11-12
Completion date
Unknown
Last updated
2025-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-abortion endometrial repair

Interventions

Experimental group:Silicone rubber uterine drug stent
Control group:Silicone rubber non-drug-loaded uterine stent

Sponsors

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1.Female patients aged between 18 and 40 years. 2.The menstrual cycle range was 21-35 days in the 6 months prior to enrollment. 3.Body Mass Index (BMI) between 18.5-28 kg/m^2 4.Voluntary termination of pregnancy, with a history of >=2 abortions or missed abortion, and confirmed gestational age <=10 weeks. 5.Voluntarily agree to enrollment, capable of regular follow-up, and able to sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1.For silicone rubber materials, individuals with known allergies or contraindications to estrogen. 2.Previous history of confirmed intrauterine adhesions by hysteroscopy or diagnosed with thin endometrium. 3.Women with uterine malformation, uterine compressing the cavity or other causes of abnormal uterine morphology. 4.Postoperative requirements include the placement of an intrauterine device or oral contraceptives, as well as subdermal implants for participants. 5.Patients with altered mental status, cognitive dysfunction, or inability to cooperate during the treatment process. 6.Researchers identified patients with potential risks or factors deemed unsuitable for inclusion.

Design outcomes

Primary

MeasureTime frame
Endometrial thickness at 21 days post-operation;

Countries

China

Contacts

Public ContactLiu Xinyan

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

liuxymeng@163.com+86 186 0000 8013

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026